AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
European Commission Approves AbbVie’s Aquipta (atogepant) for Acute Migraine Treatment
AbbVie has secured a significant regulatory endorsement from the European Commission (EC) for Aquipta (atogepant), marking a pivotal expansion of…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
AbbVie Invests $1.4 Billion in North Carolina for New Manufacturing Hub
AbbVie, a global biopharmaceutical leader, has announced a landmark $1.4 billion investment to establish its first manufacturing facility in North…
Read More
AbbVie Secures Up to $745 Million in Pain Pipeline Deal with Chinese Biopharma Haisco
AbbVie, a global biopharmaceutical giant, has finalized a significant strategic collaboration with Haisco Pharmaceutical Group, a prominent Chinese biopharmaceutical company.…
Read More
Johnson & Johnson’s Icotyde Poised to Challenge AbbVie’s Skyrizi in Plaque Psoriasis Market
The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug…
Read MoreYOU MAY HAVE MISSED
